Gilead Sciences, Inc. (GILD) to Distribute Quarterly Dividend of $0.82 on December 30th

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Thursday, October 29th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.82 per share by the biopharmaceutical company on Wednesday, December 30th. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, December 15th.

Gilead Sciences has a dividend payout ratio of 38.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Gilead Sciences to earn $9.94 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 33.0%.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $170.68 on Friday. The business’s 50 day moving average price is $150.87 and its 200 day moving average price is $139.79. The company has a market cap of $211.63 billion, a price-to-earnings ratio of -54.01 and a beta of 0.31. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences has a one year low of $114.02 and a one year high of $175.65.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.70% and a negative net margin of 12.47%. The company had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same period in the prior year, the business earned $2.47 EPS. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. On average, research analysts predict that Gilead Sciences will post -0.48 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on GILD. Jefferies Financial Group reissued a “buy” rating and issued a $185.00 price objective on shares of Gilead Sciences in a report on Friday, October 23rd. Barclays decreased their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Needham & Company LLC set a $175.00 price target on shares of Gilead Sciences in a report on Friday. Cantor Fitzgerald lifted their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $169.19.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.